Skip to main content
. 2019 Oct 27;6(11):2304–2316. doi: 10.1002/acn3.50931

Figure 3.

Figure 3

Changes in cytokine/chemokine levels after treatment in identical patients with IgG4 anti‐NF155 antibody‐positive CIDP. The Hughes FG system was used to evaluate clinical status (grade 0: normal; grade 1: minimal symptoms and signs, able to run; grade 2: able to walk 5 m independently; grade 3: able to walk 5 m with use of aids; grade 4: wheelchair user or bedbound; grade 5: requires assisted ventilation; grade 6: dead). Maximum doses of oral immunosuppressants are shown in parentheses. Unchanged or increased values in Hughes FG and cytokine/chemokine levels after treatment are indicated by bold red characters. AZA = azathioprine; CCL = C‐C motif ligand; CIDP = chronic inflammatory demyelinating polyneuropathy; CSF = cerebrospinal fluid; CyA = cyclosporine A; CXCL = C‐X‐C motif ligand; G‐CSF = granulocyte colony‐stimulating factor; Hughes FG = Hughes functional grade; IFN = interferon; IL = interleukin; IVIg = intravenous immunoglobulin; IVMP = intravenous methylprednisolone pulse therapy (1,000 mg/day for 3 consecutive days); MCP‐1 = monocyte chemoattractant protein‐1; PE = plasma exchange; PSL = prednisolone.